Priority Technology Holdings, Inc (NASDAQ:PRTH) reported fourth quarter 2025 financial results. Q4 2025 adjusted earnings at Priority Technology Holdings, ...

Q32 Bio Inc. (QTTB) reported Q4 2025 adjusted earnings of $3.65 per share. No consensus estimate was available for comparison.…

Cullinan Therapeutics posts $0.73 per share loss in Q4 2025, matching year-ago results as the pre-revenue biotech maintains clinical development…

**Tenax Therapeutics Reports Q4 2025 Results**

**BREAKING: Opus Genetics Inc. Reports Q4 2025 Results**

Apyx Medical narrows Q4 loss to $0.06 per share as revenue surges 34.8% year-over-year to $19.2 million, with fiscal 2026…

**Cullinan Therapeutics Inc Reports Q4 2025 Results**

**BREAKING: Prelude Therapeutics Reports Wider-Than-Expected Q4 Loss**

Prelude Therapeutics reports Q4 loss of $1.29/share, 616.7% wider than expected, despite revenue jumping to $12.1M from $6.5M sequentially.

Opus Genetics posts $0.80 Q4 loss as revenue surges 230% year-over-year to $14.2M on collaboration activity.